logo
  

Anixa Biosciences: FDA Asks Addl Information For CAR-T Therapy; Stock Plunges

Anixa Biosciences Inc. (ANIX) said Monday that the U.S. Food and Drug Administration has requested additional information regarding its Chimeric Antigen Receptor-T cell therapy or CAR-T being developed in partnership with Moffitt Cancer Center or MCC.

In Monday regular trading, ANIX was trading at $4.01, down $0.69 or 14.68%.

Anixa noted that the study under the Investigational New Drug or IND application has been placed on clinical hold pending submission of additional information requested by the FDA.

Anixa expects, within the next 30 days, the FDA will provide a letter to MCC with detailed and specific information requested. MCC will assemble and submit information addressing the request as soon as possible there after. Successive to the submission, the FDA will continue its review of the IND.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
When Can We Expect Starlink to Go Public? This question got an answer from Tesla and SpaceX CEO Elon Musk, who said he will only publicly list SpaceX's satellite internet service Starlink when its revenue is more predictable. Musk was responding to a users tweet, "Any thoughts on Starlink IPO we would love to invest in the future. Any thoughts on first dibs for Tesla retail investors?" John David McAfee, who founded the antivirus software company McAfee Associates, has been found dead in a prison cell in Spain shortly after a Spanish court agreed to extradite him to the US to face tax evasion charges, multiple reports said. He was arrested in Spain in October 2020 after being accused of failing to file tax returns for four years. While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) initiated its adjusted loss and total revenue guidance for the full-year 2022, below analysts' estimates. For fiscal 2022, the company now projects an adjusted loss in a range...
Follow RTT